Biogen (NASDAQ:BIIB) was downgraded to hold from buy by Jefferies, due in part to a looming royalty cut for the multiple ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Shares of Biogen Inc. BIIB slumped 0.84% to $156.46 Monday, on what proved to be an all-around dismal trading session for the ...

BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...

Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025. The firm ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Jefferies Financial Group from a “buy” ...

Beghou Consulting announced that Yair Markovits, Vishal Singal and Nicole Ventrone, have joined the company as partners. Accent Therapeutics promoted Serena Silver, PhD to chief scientific officer, ...

Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...

Jefferies downgraded Biogen (BIIB) to Hold from Buy with a price target of $180, down from $250. The firm sees a “tough setup” into 2025 for Biogen with modest Leqembi and Skyclarys US. It see a “real ...

In a report released today, Michael Yee from Jefferies downgraded Biogen (BIIB – Research Report) to a Hold, with a price target of ...